{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:25:55Z","timestamp":1788200755965,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00270-022-03224-w","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T18:02:49Z","timestamp":1658426569000},"page":"1288-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Bleomycin Slow Infusion Sclerotherapy Using a Syringe Pump for Microcystic and Mixed Lymphatic Malformations"],"prefix":"10.1007","volume":"45","author":[{"given":"Jung Guen","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-8229","authenticated-orcid":false,"given":"Sang Yub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihoon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"3224_CR1","unstructured":"The International Society for the Study of Vascular Anomalies (ISSVA). ISSVA classification. 2018. Available online: https:\/\/www.issva.org\/UserFiles\/file\/ISSVA-Classification-2018.pdf. Accessed 2 Feb 2022."},{"issue":"10","key":"3224_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archotol.128.10.1137","volume":"128","author":"CM Giguere","year":"2002","unstructured":"Giguere CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg. 2002;128(10):1137\u201344.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"10","key":"3224_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jvir.2011.06.021","volume":"22","author":"G Chaudry","year":"2011","unstructured":"Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI. Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol. 2011;22(10):1431\u20135.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"3224_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s00247-012-2406-2","volume":"42","author":"A Shergill","year":"2012","unstructured":"Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol. 2012;42(9):1080\u20138.","journal-title":"Pediatr Radiol"},{"issue":"5","key":"3224_CR5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1097\/PRS.0b013e31820e923c","volume":"127","author":"DCG Sainsbury","year":"2011","unstructured":"Sainsbury DCG, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg. 2011;127(5):2031\u201344.","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"3224_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00383-003-1058-6","volume":"19","author":"T Muir","year":"2004","unstructured":"Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int. 2004;19(12):766\u201373.","journal-title":"Pediatr Surg Int"},{"issue":"1","key":"3224_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1148\/radiol.2017162076","volume":"287","author":"Y Jin","year":"2018","unstructured":"Jin Y, Zou Y, Hua C, Chen H, Yang X, Ma G, et al. Treatment of early-stage extracranial arteriovenous malformations with intralesional interstitial bleomycin injection: a pilot study. Radiology. 2018;287(1):194\u2013204.","journal-title":"Radiology"},{"issue":"6","key":"3224_CR8","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s00270-014-0932-z","volume":"37","author":"G Chaudry","year":"2014","unstructured":"Chaudry G, Guevara CJ, Rialon KL, Kerr C, Mulliken JB, Greene AK, et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Intervent Radiol. 2014;37(6):1476\u201381.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3224_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3348\/jksr.2016.74.1.26","volume":"74","author":"J Lee","year":"2016","unstructured":"Lee J, Lee SJ, Chung HY, et al. Infusion sclerotherapy of microcystic lymphatic malformation: clinico-radiological mid-term results. J Korean Soc Radiol. 2016;74:26\u201336.","journal-title":"J Korean Soc Radiol"},{"issue":"2","key":"3224_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3174\/ajnr.A5449","volume":"39","author":"V Da Ros","year":"2018","unstructured":"Da Ros V, Iacobucci M, Puccinelli F, Spelle L, Saliou G. Lymphographic-like technique for the treatment of microcystic lymphatic malformation components of < 3 mm. AJNR Am J Neuroradiol. 2018;39(2):350\u20134.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"8","key":"3224_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141\u20136.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"3224_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/1097-0142(1967)20:5<891::AID-CNCR2820200550>3.0.CO;2-V","volume":"20","author":"H Umezawa","year":"1967","unstructured":"Umezawa H, Ishizuka M, Maeda K, Takeuchi T. Studies on bleomycin. Cancer. 1967;20(5):891\u20135.","journal-title":"Cancer"},{"issue":"1","key":"3224_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0027-5107(90)90110-P","volume":"232","author":"D Lopez-Larraza","year":"1990","unstructured":"Lopez-Larraza D, De Luca JC, Bianchi NO. The kinetics of DNA damage by bleomycin in mammalian cells. Mutat Res. 1990;232(1):57\u201361.","journal-title":"Mutat Res"},{"issue":"4","key":"3224_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N","volume":"31","author":"RH Blum","year":"1973","unstructured":"Blum RH, Carter SK, Agre K. A clinical review of bleomycin\u2014a new antineoplastic agent. Cancer. 1973;31(4):903\u201314.","journal-title":"Cancer"},{"issue":"2","key":"3224_CR15","doi-asserted-by":"publisher","first-page":"L193","DOI":"10.1152\/ajplung.00349.2010","volume":"302","author":"H Ohta","year":"2012","unstructured":"Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T. Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;302(2):L193-205.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"3224_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.bjoms.2017.10.002","volume":"55","author":"L McMorrow","year":"2017","unstructured":"McMorrow L, Shaikh M, Kessell G, Muir T. Bleomycin electrosclerotherapy: new treatment to manage vascular malformations. Br J Oral Maxillofac Surg. 2017;55(9):977\u20139.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"3","key":"3224_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jvsv.2020.09.009","volume":"9","author":"WA Wohlgemuth","year":"2021","unstructured":"Wohlgemuth WA, Muller-Wille R, Meyer L, Wildgruber M, Guntau M, Heydt SV, et al. Bleomycin electrosclerotherapy in therapy-resistant venous malformations of the body. J Vasc Surg Venous Lymphat Disord. 2021;9(3):731\u20139.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"6","key":"3224_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bph.12355","volume":"170","author":"W Zhang","year":"2013","unstructured":"Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol. 2013;170(6):1210\u201320.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3224_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000225462","volume":"37","author":"RL Levy","year":"1980","unstructured":"Levy RL, Chiarillo S. Hyperpyrexia, allergic-type response and death occurring with low-dose bleomycin administration. Oncology. 1980;37(5):316\u20137.","journal-title":"Oncology"},{"key":"3224_CR20","doi-asserted-by":"crossref","unstructured":"Mendez-Echevarria A, Fernandez-Prieto A, de la Serna O, Lopez-Gutierrez JC, Parron M, Marin-Aguilera B, et al. Acute lung toxicity after intralesional bleomycin sclerotherapy. Pediatrics. 2018;141(1).","DOI":"10.1542\/peds.2016-1787"},{"issue":"1","key":"3224_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/annonc\/mdg020","volume":"14","author":"JM O'Sullivan","year":"2003","unstructured":"O\u2019Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91\u20136.","journal-title":"Ann Oncol"},{"issue":"2 Suppl 5","key":"3224_CR22","first-page":"64","volume":"19","author":"RL Comis","year":"1992","unstructured":"Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol. 1992;19(2 Suppl 5):64\u201370.","journal-title":"Semin Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03224-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03224-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03224-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T22:05:41Z","timestamp":1662674741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03224-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03224-w","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. Institutional Review Board (IRB) approval was obtained for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Indivisual written informed consents for the sclerotherapy procedures were obtained from all patients or their authorized trustees.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}